NDAORALSOLUTION
Approved
Jul 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
QBRELIS (lisinopril) by R-Pharm US is angiotensin-converting enzyme (ace) in human subjects and animals. Approved for hypertension, heart failure, diabetic nephropathy. First approved in 2016.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QBRELIS (lisinopril) is an oral ACE inhibitor solution approved in 2016 that suppresses the renin-angiotensin-aldosterone system to reduce blood pressure and improve cardiac function. It treats hypertension, heart failure, diabetic nephropathy, and multiple cardiovascular and renal conditions by blocking angiotensin II formation and aldosterone secretion. The drug is indicated across a broad patient population including those with diabetes, chronic kidney disease, and left ventricular dysfunction.
$1MPart D
Peak9.5 years to LOEProduct is at peak maturity with minimal Part D penetration, suggesting established market position with stable but modest commercial opportunity.
Mechanism of Action
angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of…
Indications (3)
Worked on QBRELIS at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.